Associate professor Mohamed Kamal
Associate Professor
220 building K
My name is Mohamed M. Kamal, Associate Prof. of Biochemistry. I was graduated from Faculty of Pharmacy, Ain Shams University in 2001 with overall grade Excellent with Honor. After graduation, I worked as teaching assistant in Biochemistry Department, Faculty of Pharmacy, Ain Shams University. I got my Master degree in 2006 on diabetic cardiovascular complications. Then, I got my Ph.D. in 2011 on glioblastoma cancer stem cells, during which, I joined Sadhan Majumder's lab in Genetics Department, M.D. Anderson Cancer Center, Houston, Texas, USA from 2008 through 2010 as part of Joint Supervision scholarship from Egyptian Government. After my Ph.D., I have been working as Lecturer of Biochemistry in the Biochemistry Department, Faculty of Pharmacy, Ain Shams University, where I managed to start a stem cell line of research. Meanwhile, I managed to get a Fulbright postdoctoral fellowship from October, 2014 - July 2015 in M.D. Anderson Cancer Center, doing more research on brain tumor. 
Recently, I got promoted to Associate Prof. in June, 2017 after which I joined the BUE. My academic goal is to dedicate my efforts and time to attain excellence in teaching undergraduates and training post graduates. I am looking forward to actively participate in pharmacy education, scholar activities and services in BUE. Meanwhile, I am looking forward to keep my research productivity, initiate a research lab for training both under and postgraduates, collaborate scientifically with new scientists. All of the this with the ultimate goal of better understanding of the molecular mechanisms of diseases and developing new therapeutic strategies to provide better health outcomes for our patients. Also, I am looking forward to be a distinguished scientist in field of stem cells and gene therapy.

2007-2011 Ph.D. of Pharmacy (Biochemistry) Joint Supervision between M.D. Anderson Cancer Center, Houston, Texas, USA and Faculty of Pharmacy,Ain Shams University, Cairo, Egypt   

2002-2006 M.Sc. of Pharmacy (Biochemistry), Faculty of Pharmacy,Ain Shams University,Cairo, Egypt 

1996-2001 B.Sc. of Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Journal Articles

1) REST regulates oncogenic properties of glioblastoma stem cells. Mohamed M. Kamal*, Pratheesh Sathyan*, Sanjay K. Singh, Pascal O. Zinn, Anantha L. Marisetty, Shoudan Liang, Joy Gumin, Hala Osman El-Mesallamy, Dima Suki, Howard Colman, Gregory Fuller, Fredrick Lang, and Sadhan Majumder (2012) Stem Cells, 30:405-414
*co-first author

2) A comparison of Wharton’s jelly versus cord blood as a source of mesenchymal stem cells for diabetes cell therapy. Rasha F. El-Demerdash, Lamiaa N. Hammad, Mohamed M. Kamal and Hala O. El-Mesallamy (2015) Regenerative Medicine,10(7):841-55. Epub 2015 Nov 6.

3) Mir-21–Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. Pratheesh Sathyan*, Pascal O.Zinn*, Anantha L.Marisetty*, Bin Liu*, Mohamed Mostafa Kamal*, Sanjay K. Singh, PierreBady, * Li Lu, Khalida M.Wani, Bethany L.Veo, Joy Gumin, Dina Hamada Kassem, Frederick Robinson, Connie Weng, Veerabhadran Baladandayuthapani, Dima Suki, Howard Colman, Krishna P. Bhat, Erik
Mohamed Kamal Phone: 00201000196335
P.Sulman, Ken Aldape, Rivka R.Colen, Roel G.W.Verhaak, Zhimin Lu, Gregory N.Fuller, Suyun Huang, Frederick F.Lang, Raymond Sawaya, Monika Hegi, and Sadhan Majumder (2015)The Journal of Neuroscience-11;35(45):15097-112.
*co-first author

4) Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarianfailure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1). Said RS, El-Demerdash E, Nada AS, Kamal MM.(2015) Biochemical Pharmacology 1;103:140-50

5) Association of expression levels of pluripotency/stem cell markers with the differentiation outcome of Wharton's jelly mesenchymal stem cells into insulin producing cells. Kassem DH*, Kamal MM*, El-Kholy Ael-L, El-Mesallamy HO (2016) Biochimie. 127:187-95.
*co-first author

6) Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers. Kassem DH*, Kamal MM*, El-Kholy Ael-L, El-Mesallamy HO (2016) StemCell Research and Therapy 11;7(1):108
*co-first author

7) Association of serum Pancreatic derived factor (PANDER) with beta-cell dysfunction in type 2 diabetes mellitus Miral M. Shehata, Mohamed M. Kamal, Mohamed H. El-Hefnawy and Hala O. EL-Mesallamy (2017) Journal of Diabetes and its Complications, 31(4):748-752

8) Comparing Umbilical Cord Blood Stem cells and Wharton’s Jelly Mesenchymal stem cells regarding their differentiation potential to Insulin Producing cells. MM Kamal, HO EL-Mesallamy, LN-Hammad and RF EL-Demerdash (2014) Cytotherapy supplement, 16 (45):S66

9) Isolation of Wharton’s Jelly mesenchymal stem cells and their differentiation into Insulin producing cells DH Kassem, MM Kamal, HO EL-Mesallamy and A. El-Kholy (2014) Cytotherapy supplement, 16 (45):S66

10) Obestatin can potentially differentiate Wharton’s jelly mesenchymal stem cells into insulin-producing cells
RK El-Asfar, MM Kamal, RS Abd EL-Razek, E EL-Demerdash and HO El-Mesallamy (2018) Cell and Tissue Research, 372 (1): 91–98

11) Serum Vit-D and Its Upregulated Protein, Thioredoxin Interacting Protein, are Associated with β-Cell Dysfunction in Type 1 and Type 2 Diabetic Patients
Doaa F. Omar, Mohamed M. Kamal, Mohamed H. El-Hefnawy, Hala O. EL-Mesallamy (2018) Canadian Journal of Diabetes, 42 (6): 588-594
Mohamed Kamal Phone: 00201000196335

12) REST overexpression in mice causes deficits in spontaneous locomotion
Li Lu, Anantha Marisetty, Bin Liu, Mohamed Mostafa Kamal, Joy Gumin, Bethany Veo, YouQing Cai, Dina Hamada Kassem, Connie Weng, Mark E. Maynard, Kimberly N. Hood, Gregory N. Fuller, Zhizhong Z. Pan, Matthew D. Cykowski, Pramod K. Dash & Sadhan Majumder (2018) Scientific Reports, Volume 8

13) REST-DRD2 mechanism impacts glioblastoma stem cell–mediated tumorigenesis.
Anantha L Marisetty, Li Lu, Bethany L Veo, Bin Liu, Cristian Coarfa, Mohamed Mostafa Kamal, Dina Hamada Kassem, Khushboo Irshad, Yungang Lu, Joy Gumin,
Verlene Henry, Adriana Paulucci-Holthauzen, Ganesh Rao, Veerabhadran Baladandayuthapani, Frederick F Lang, Gregory N Fuller, Sadhan Majumder
Neuro-Oncology, June 2019, 21(6), pp. 775-785

14) Coenzyme Q10 mitigates ionizing radiation-induced testicular damage in rats through inhibition of oxidative stress and mitochondria-mediated apoptotic cell death Said, R.S., Mohamed, H.A., Kamal, M.M. Toxicol Appl Pharmacol. 2019 Nov 15;383:114780.

15) Wharton's Jelly MSCs: Potential Weapon to Sharpen for Our Battle against DM.
Kassem, D.H and Kamal, M.M Trends in Endocrinology and Metabolism Volume 31, Issue 4, April 2020, Pages 271-273.

16) Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges Kamal, M.M. and Kassem, D.H. Frontiers in Cell and Developmental Biology, Volume 8, 29 January 2020, Article number 16

17) Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study Dina H. Kassem & Mohamed M. Kamal Stem Cell Research & Therapy volume 11, Article number: 484 (2020), November 2020 18) Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis Dina H. Kassem and Mohamed M. Kamal, Front. Cell Dev. Biol., 30 September 2020

19) Effects of Chronic Caffeine Administration on Behavioral and Molecular Adaptations to Sensory Contact Model Induced Stress in Adolescent Male Mice Michael Kamal Ibrahim, Mohamed Kamal, Rajiv Tikamdas, Roua Aref Nouh, Jiang Tian & Moustafa Sayed, Behavior Genetics, volume 50, pages374–383, June 2020

20) A Novel SERPINB1 Single-Nucleotide Polymorphism Associated With Glycemic Control and β-Cell Function in Egyptian Type 2 Diabetic Patients Dina H. Kassem, Aya Adel, Ghada H. Sayed and Mohamed M. Kamal Front. Endocrinol., July 2020 (

Fields of Interests
I. Stem cell biology We are interested in the isolation of mesenchymal stem cells from different sources including umbilical cord, bone marrow and adipose tissue. Consequently, we are examining the differentiation of these cells into different lineages with special interest in the differentiation of mesenchymal stem cells into insulin producing cells for diabetes treatment. Our overall aim is to study how to improve the differentiation of mesenchymal stem cell into other cell types both in-vitro and in-vivo for better cell therapy outcomes of different diseases. II. β-cell dysfunction in diabetes mellitus (DM) We are interested in studying the β-cell dysfunction as a major determinant of type 1 and type 2 diabetes mellitus. We tried to measure some biochemical markers that closely reflect the β-cell function to be used as clinical markers of β-cell status in diabetic patients of different types of diabetes. III. Glioblastoma cancer stem cells We were interested in the role of the transcription factor REST in the oncogenesis of the glioblastoma (GBM) cancer stem cells. Also, we examined the use of the microRNA 21 (mir21) - Sox2, a pluripotency marker, axis in the clinical prognostic classification of GBM tumors.
Module leader for different biochemistry modules Member of Quality management and development Committee Member of the Faculty of Pharmacy Council Supervisor of Research methodology- Fifth year students’ group